Creo Medical Group (LON:CREO) Trading Up 3.6% - What's Next?

Key Points

• Shares rose 3.6% to GBX 12.56 (intraday high GBX 13) with approximately 728,823 shares traded, about 13% below the average daily volume.
• Shore Capital Group reissued a "house stock" rating on Creo on April 16, maintaining analyst coverage.
• Creo develops minimally invasive electrosurgical devices (CROMA/Kamaptive); the company has a market cap of £51.8M, a negative P/E of -12.56, and 50/200-day moving averages near GBX 12.60/12.10.

Shares of Creo Medical Group PLC (LON:CREO - Get Free Report) were up 3.6% on Thursday . The stock traded as high as GBX 13 and last traded at GBX 12.56. Approximately 728,823 shares changed hands during trading, a decline of 13% from the average daily volume of 837,861 shares. The stock had previously closed at GBX 12.13.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reissued a "house stock" rating on shares of Creo Medical Group in a report on Thursday, April 16th.

Creo Medical Group Price Performance

The company's fifty day moving average price is GBX 12.60 and its 200 day moving average price is GBX 12.10. The company has a debt-to-equity ratio of 6.90, a quick ratio of 2.19 and a current ratio of 5.28. The firm has a market capitalization of £51.81 million, a price-to-earnings ratio of -12.56 and a beta of 1.50.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.